Orchestra BioMed Holdings (OBIO) Cash from Operations Growth (1y) (2022 - 2026)
Orchestra BioMed Holdings (OBIO) Cash from Operations Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,290.43 Bn | 66,290.15 Bn | - | 7.14% |
| 2 | Nanobiotix | 1,914.07 Bn | 1,914.01 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 467.97 Bn | 463.18 Bn | 1.35 Bn | 356.73% |
| 5 | Vertex Pharmaceuticals | 122.73 Bn | 115.48 Bn | 2.59 Bn | 74.39% |
| 6 | Regeneron Pharmaceuticals | 70.42 Bn | 61.67 Bn | 3.31 Bn | 3.23% |
| 7 | Belite Bio | 62.82 Bn | 62.82 Bn | - | - |
| 8 | Argenx Se | 56.00 Bn | 50.82 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.51 Bn | 34.50 Bn | 959.66 Mn | 158.60% |
| 10 | Orchestra BioMed Holdings | 238.97 Mn | 144.57 Mn | 78,000.00 | -33.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.41% |
| Dec 31, 2025 | 83.23% |
| Sep 30, 2025 | -6.20% |
| Jun 30, 2025 | -52.14% |
| Mar 31, 2025 | -26.70% |
| Dec 31, 2024 | -23.36% |
| Sep 30, 2024 | -33.24% |
| Jun 30, 2024 | 2.71% |
| Mar 31, 2024 | 8.81% |
| Dec 31, 2023 | -25.50% |
| Sep 30, 2023 | -41.70% |
| Jun 30, 2023 | -31.70% |
| Mar 31, 2023 | -170.12% |
| Dec 31, 2022 | -30,224.26% |
| Sep 30, 2022 | -5,568.31% |
| Jun 30, 2022 | -20,248.47% |
| Mar 31, 2022 | -6,870.96% |